<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AZATHIOPRINE- azathioprine tablet </strong><br>Mylan Institutional Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_f3ea1841-bf9f-4956-83cc-98da31a133ae"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">WARNING: </span>Chronic <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> with this purine antimetabolite increases <span class="Italics">risk of neoplasia </span>in humans. Physicians using this drug should be very familiar with the risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. See <a href="#i4i_warnings_id_da19e3c9-77ce-47f9-8707-52c7a4018fa1">WARNINGS</a>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_335fedde-8ddf-444c-b94d-8f095f62ada8"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Azathioprine tablets USP, an immunosuppressive antimetabolite, is available in tablet form for oral administration. Each scored tablet contains 50 mg azathioprine, USP and the inactive ingredients corn starch, lactose monohydrate, magnesium stearate, povidone, and stearic acid.</p>
<p>Azathioprine is chemically 6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine.</p>
<p>The structural formula of azathioprine is:</p>
<div class="Figure">
<a name="id255"></a><img alt="Azathioprine Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e385894f-212b-4582-a63a-a0767fd97645&amp;name=4a0b69ca-0539-4e36-9cdc-3caa663795c5-01.jpg">
</div>
<p>It is an imidazolyl derivative of 6-mercaptopurine and many of its biological effects are similar to those of the parent compound.</p>
<p>Azathioprine is insoluble in water, but may be dissolved with addition of one molar equivalent of alkali. The sodium salt of azathioprine is sufficiently soluble to make a 10 mg/mL water solution which is stable for 24 hours at 59° to 77°F (15° to 25°C). Azathioprine is stable in solution at neutral or acid pH but hydrolysis to mercaptopurine occurs in excess sodium hydroxide (0.1N), especially on warming. Conversion to mercaptopurine also occurs in the presence of sulfhydryl compounds such as cysteine, glutathione, and hydrogen sulfide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_df034bd4-87d9-40b3-99f9-5bfe3d8cf37d"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Azathioprine is well absorbed following oral administration. Maximum serum radioactivity occurs at 1 to 2 hours after oral <span class="Sup">35</span>S-azathioprine and decays with a half-life of 5 hours. This is not an estimate of the half-life of azathioprine itself, but is the decay rate for all <span class="Sup">35</span>S-containing metabolites of the drug. Because of extensive metabolism, only a fraction of the radioactivity is present as azathioprine. Usual doses produce blood levels of azathioprine, and of mercaptopurine derived from it, which are low (&lt; 1 mcg/mL). Blood levels are of little predictive value for therapy since the magnitude and duration of clinical effects correlate with thiopurine nucleotide levels in tissues rather than with plasma drug levels. Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable. See <a href="#i4i_overdosage_id_a5349abb-f776-4f73-82cc-6a1289fe8345">OVERDOSAGE</a>.</p>
<p> Azathioprine is metabolized to 6-mercaptopurine (6-MP). Both compounds are rapidly eliminated from blood and are oxidized or methylated in erythrocytes and liver; no azathioprine or mercaptopurine is detectable in urine after 8 hours. Activation of 6-mercaptopurine occurs via hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and a series of multi-enzymatic processes involving kinases to form 6-thioguanine nucleotides (6-TGNs) as major metabolites (See Metabolism Scheme in Figure 1). The cytotoxicity of azathioprine is due, in part, to the incorporation of 6-TGN into DNA.</p>
<p> 6-MP undergoes two major inactivation routes (Figure 1). One is thiol methylation, which is catalyzed by the enzyme thiopurine S-methyltransferase (TPMT), to form the inactive metabolite methyl-6-MP (6-MeMP). TPMT activity is controlled by a genetic polymorphism.<span class="Sup">1, 2, 3</span> For Caucasians and African Americans, approximately 10% of the population inherit one nonfunctional TPMT allele (heterozygous) conferring intermediate TPMT activity, and 0.3% inherit two TPMT nonfunctional alleles (homozygous) for low or absent TPMT activity. Nonfunctional alleles are less common in Asians. TPMT activity correlates inversely with 6-TGN levels in erythrocytes and presumably other hematopoietic tissues, since these cells have negligible xanthine oxidase (involved in the other inactivation pathway) activities, leaving TPMT methylation as the only inactivation pathway. Patients with intermediate TPMT activity may be at increased risk of myelotoxicity if receiving conventional doses of azathioprine tablets. Patients with low or absent TPMT activity are at an increased risk of developing severe, life threatening myelotoxicity if receiving conventional doses of azathioprine tablets. <span class="Sup">4-9 </span>TPMT genotyping or phenotyping (red blood cell TPMT activity) can help identify patients who are at an increased risk for developing azathioprine toxicity.<span class="Sup">2, 3, 7, 8, 9</span> Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. See <a href="#i4i_warnings_id_da19e3c9-77ce-47f9-8707-52c7a4018fa1">WARNINGS</a>, <a href="#i4i_interactions_id_633d8de3-cf51-4abe-b607-73d61b8566e8">PRECAUTIONS: Drug Interactions</a>, <a href="#i4i_lab_tests_id_6488bc0c-14b2-4c9f-855a-43a66e04b55d">PRECAUTIONS: Laboratory Tests</a> and <a href="#i4i_adverse_effects_id_eaa77ecc-3919-44c0-92c4-ee850ed35eac">ADVERSE REACTIONS</a> sections.</p>
<div class="Figure">
<a name="id283"></a><img alt="Figure 1. Metabolism pathway of azathioprine: competing pathways result in inactivation by TPMT or XO, or incorporation of cytotoxic nucleotides into DNA." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e385894f-212b-4582-a63a-a0767fd97645&amp;name=4a0b69ca-0539-4e36-9cdc-3caa663795c5-02.jpg"><p class="MultiMediaCaption">Figure 1. Metabolism pathway of azathioprine: competing pathways result in inactivation by TPMT or XO, or incorporation of cytotoxic nucleotides into DNA. </p>
</div>
<p>GMPS: Guanosine monophosphate synthetase; HGPRT: Hypoxanthine-guanine-phosphoribosyl-transferase; IMPD: Inosine monophosphate dehydrogenase; MeMP: Methylmercaptopurine; MeMPN: Methylmercaptopurine nucleotide; TGN: Thioguanine nucleotides; TIMP: Thioinosine monophosphate; TPMT: Thiopurine S-methyltransferase; TU: Thiouric acid; XO: Xanthine oxidase (Adapted from <span class="Italics">Pharmacogenomics </span>2002; 3:89-98; and <span class="Italics">Cancer Res </span>2001; 61:5810-5816.)</p>
<p> Another inactivation pathway is oxidation, which is catalyzed by xanthine oxidase (XO) to form 6-thiouric acid. The inhibition of xanthine oxidase in patients receiving allopurinol is the basis for the azathioprine dosage reduction required in these patients (see <a href="#i4i_interactions_id_633d8de3-cf51-4abe-b607-73d61b8566e8">PRECAUTIONS: Drug Interactions</a>). Proportions of metabolites are different in individual patients, and this presumably accounts for variable magnitude and duration of drug effects. Renal clearance is probably not important in predicting biological effectiveness or toxicities, although dose reduction is practiced in patients with poor renal function.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1de97f1c-bf13-44f6-a24a-ab2e1401f5ee"></a><a name="section-2.1"></a><p></p>
<h2>Homograft Survival</h2>
<p class="First">The use of azathioprine for inhibition of renal homograft rejection is well established, the mechanism(s) for this action are somewhat obscure. The drug suppresses hypersensitivities of the cell-mediated type and causes variable alterations in antibody production. Suppression of T-cell effects, including ablation of T-cell suppression, is dependent on the temporal relationship to antigenic stimulus or engraftment. This agent has little effect on established <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">graft rejections</span> or secondary responses.</p>
<p> Alterations in specific immune responses or immunologic functions in transplant recipients are difficult to relate specifically to <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> by azathioprine. These patients have subnormal responses to vaccines, low numbers of T-cells, and abnormal phagocytosis by peripheral blood cells, but their mitogenic responses, serum immunoglobulins, and secondary antibody responses are usually normal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_98ee757b-5fe7-48cc-bcac-75023da26fec"></a><a name="section-2.2"></a><p></p>
<h2>Immunoinflammatory Response</h2>
<p class="First">Azathioprine suppresses disease manifestations as well as underlying pathology in animal models of autoimmune disease. For example, the severity of adjuvant <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> is reduced by azathioprine.</p>
<p> The mechanisms whereby azathioprine affects autoimmune diseases are not known. Azathioprine is immunosuppressive, delayed <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and cellular cytotoxicity tests being suppressed to a greater degree than are antibody responses. In the rat model of adjuvant <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, azathioprine has been shown to inhibit the lymph node <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, which precedes the onset of the signs of the disease. Both the immunosuppressive and therapeutic effects in animal models are dose related. Azathioprine is considered a slow-acting drug and effects may persist after the drug has been discontinued.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_c1b599f7-ec14-4d23-82af-55e7fe8bf10c"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Azathioprine tablets are indicated as an adjunct for the prevention of rejection in renal homotransplantation. It is also indicated for the management of active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> to reduce signs and symptoms.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5824b901-1494-4e7c-8a8a-de4d23c0f89c"></a><a name="section-3.1"></a><p></p>
<h2>Renal Homotransplantation</h2>
<p class="First">Azathioprine tablets are indicated as an adjunct for the prevention of rejection in renal homotransplantation. Experience with over 16,000 transplants shows a 5-year patient survival of 35% to 55% but this is dependent on donor, match for HLA antigens, anti-donor or anti B-cell alloantigen antibody, and other variables. The effect of azathioprine tablets on these variables has not been tested in controlled trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e4731ce6-842f-4bdb-8efc-babf4b94dbaa"></a><a name="section-3.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></h2>
<p class="First">Azathioprine tablets are indicated for the treatment of active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (RA) to reduce signs and symptoms. Aspirin, non-steroidal anti-inflammatory drugs and/or low dose glucocorticoids may be continued during treatment with azathioprine tablets. The combined use of azathioprine tablets with disease modifying anti-rheumatic drugs (DMARDs) has not been studied for either added benefit or unexpected adverse effects. The use of azathioprine tablets with these agents cannot be recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_bf50f97a-e0f7-4003-b677-97db2968ac7c"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Azathioprine tablets should not be given to patients who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug. Azathioprine tablets should not be used for treating <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> in pregnant women. Patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> previously treated with alkylating agents (cyclophosphamide, chlorambucil, melphalan, or others) may have a prohibitive risk of neoplasia if treated with azathioprine tablets.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_da19e3c9-77ce-47f9-8707-52c7a4018fa1"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Severe <span class="Italics"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4308125" conceptname="Macrocytic anemia">macrocytic anemia</span></span>, and/or <span class="Italics"><span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span></span> may occur in patients being treated with azathioprine tablets. Severe bone marrow suppression may also occur. Patients with intermediate thiopurine S-methyl transferase (TPMT) activity may be at an increased risk of myelotoxicity if receiving conventional doses of azathioprine tablets. Patients with low or absent TPMT activity are at an increased risk of developing severe, life threatening myelotoxicity if receiving conventional doses of azathioprine tablets. TPMT genotyping or phenotyping can help identify patients who are at an increased risk for developing azathioprine tablet toxicity.<span class="Sup">2-9</span> (See <a href="#i4i_lab_tests_id_6488bc0c-14b2-4c9f-855a-43a66e04b55d">PRECAUTIONS: Laboratory Tests</a>.) Hematologic toxicities are dose related and may be more severe in renal transplant patients whose homograft is undergoing rejection. It is suggested that patients on azathioprine tablets have complete blood counts, including platelet counts, weekly during the first month, twice monthly for the second and third months of treatment, then monthly or more frequently if dosage alterations or other therapy changes are necessary. Delayed hematologic suppression may occur. Prompt reduction in dosage or temporary withdrawal of the drug may be necessary if there is a rapid <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in or persistently low leukocyte count, or other evidence of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>. <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> does not correlate with therapeutic effect; therefore the dose should not be increased intentionally to lower the white blood cell count.</p>
<p><span class="Italics">Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span> are a constant hazard for patients receiving chronic <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>, especially for homograft recipients. Fungal, viral, bacterial, and protozoal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may be fatal and should be treated vigorously. Reduction of azathioprine dosage and/or use of other drugs should be considered.</p>
<p> Azathioprine tablets are mutagenic in animals and humans, carcinogenic in animals, and may increase the patient’s <span class="Italics">risk of neoplasia</span>. Renal transplant patients are known to have an increased risk of malignancy, predominantly skin cancer and reticulum cell or lymphomatous tumors. The risk of post-transplant <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> may be increased in patients who receive aggressive treatment with immunosuppressive drugs. The degree of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> is determined, not only by the immunosuppressive regimen, but also by a number of other patient factors. The number of immunosuppressive agents may not necessarily increase the risk of post-transplant <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>. However, transplant patients who receive multiple immunosuppressive agents may be at risk for over-<span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>; therefore, immunosuppressive drug therapy should be maintained at the lowest effective levels. Information is available on the spontaneous neoplasia risk in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, and on neoplasia following immunosuppressive therapy of other autoimmune diseases. It has not been possible to define the precise risk of neoplasia due to azathioprine tablets. The data suggest the risk may be elevated in patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, though lower than for renal transplant patients. However, acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> as well as <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> have been reported in patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> who have received azathioprine. Data on neoplasia in patients receiving azathioprine tablets can be found under ADVERSE REACTIONS.</p>
<p> Azathioprine tablets has been reported to cause temporary <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> in spermatogenesis and reduction in sperm viability and sperm count in mice at doses 10 times the human therapeutic dose;<span class="Sup">10</span> a reduced percentage of fertile matings occurred when animals received 5 mg/kg. <span class="Sup">11</span></p>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_baad16bf-90f1-4116-8537-c1822e00af2a"></a><a name="section-5.1"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_35d76293-ba93-4db0-8e65-6999d1a8e600"></a><a name="section-5.1.1"></a><p></p>
<h3>Pregnancy Category D</h3>
<p class="First">Azathioprine tablets can cause fetal harm when administered to a pregnant woman. Azathioprine tablets should not be given during pregnancy without careful weighing of risk versus benefit. Whenever possible, use of azathioprine tablets in pregnant patients should be avoided. This drug should not be used for treating <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> in pregnant women. <span class="Sup">12</span></p>
<p> Azathioprine tablets are teratogenic in rabbits and mice when given in doses equivalent to the human dose (5 mg/kg daily). Abnormalities included skeletal malformations and visceral anomalies. <span class="Sup">11</span></p>
<p> Limited immunologic and other abnormalities have occurred in a few infants born of renal allograft recipients on azathioprine tablets. In a detailed case report, <span class="Sup">13</span> documented <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>, diminished IgG and IgM levels, <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span>, and a decreased thymic shadow were noted in an infant born to a mother receiving 150 mg azathioprine and 30 mg prednisone daily throughout pregnancy. At 10 weeks most features were normalized. DeWitte et al reported <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> and severe immune deficiency in a preterm infant whose mother received 125 mg azathioprine and 12.5 mg prednisone daily. <span class="Sup">14</span> There have been two published reports of abnormal physical findings. Williamson and Karp described an infant born with preaxial <span class="product-label-link" type="condition" conceptid="74740" conceptname="Polydactyly">polydactyly</span> whose mother received azathioprine 200 mg daily and prednisone 20 mg every other day during pregnancy. <span class="Sup">15</span> Tallent et al described an infant with a large <span class="product-label-link" type="condition" conceptid="4212197" conceptname="Meningomyelocele">myelomeningocele</span> in the upper lumbar region, bilateral dislocated hips, and bilateral <span class="product-label-link" type="condition" conceptid="438242" conceptname="Talipes equinovarus">talipes equinovarus</span>. The father was on long-term azathioprine therapy. <span class="Sup">16</span></p>
<p> Benefit versus risk must be weighed carefully before use of azathioprine tablets in patients of reproductive potential. There are no adequate and well controlled studies in pregnant women. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing age should be advised to avoid becoming pregnant.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_bec768e0-4d9d-485d-8c61-c72d16dd0a6f"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_f0d4e83b-99da-4d02-9687-76976ce3adbe"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">A gastrointestinal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> characterized by severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> has been reported. These symptoms may also be accompanied by <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, elevations in liver enzymes, and occasionally, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Symptoms of <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">gastrointestinal toxicity</span> most often develop within the first several weeks of therapy with azathioprine tablets and are reversible upon discontinuation of the drug. The reaction can recur within hours after rechallenge with a single dose of azathioprine tablets.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_7883172f-d3dc-400a-9744-4e862a010aa8"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients being started on azathioprine tablets should be informed of the necessity of periodic blood counts while they are receiving the drug and should be encouraged to report any unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> to their physician. They should be informed of the danger of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> while receiving azathioprine tablets and asked to report signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to their physician. Careful dosage instructions should be given to the patient, especially when azathioprine tablets are being administered in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> or concomitantly with allopurinol (see <a href="#i4i_dosage_admin_id_001e484d-2965-4ed3-ba3a-f97ac5d4cc8b">DOSAGE AND ADMINISTRATION</a> and <a href="#i4i_interactions_id_633d8de3-cf51-4abe-b607-73d61b8566e8">PRECAUTIONS: Drug Interactions</a>). Patients should be advised of the potential risks of the use of azathioprine tablets during pregnancy and during the nursing period. The increased risk of neoplasia following therapy with azathioprine tablets should be explained to the patient.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_6488bc0c-14b2-4c9f-855a-43a66e04b55d"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_44fe9f6a-1acf-4a3f-b029-09b3f10f8824"></a><a name="section-6.3.1"></a><p></p>
<h3>Complete Blood Count (CBC) Monitoring</h3>
<p class="First">Patients on azathioprine tablets should have complete blood counts, including platelet counts, weekly during the first month, twice monthly for the second and third months of treatment, then monthly or more frequently if dosage alterations or other therapy changes are necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c5c6c859-4c3a-474e-b115-197a36427d5c"></a><a name="section-6.3.2"></a><p></p>
<h3>TPMT Testing</h3>
<p class="First">It is recommended that consideration be given to either genotype or phenotype patients for TPMT. Phenotyping and genotyping methods are commercially available. The most common non-functional alleles associated with reduced levels of TPMT activity are TPMT*2, TPMT*3A and <span class="Bold"><span class="Italics">TPMT*3C</span></span>. Patients with two nonfunctional alleles (homozygous) have low or absent TPMT activity and those with one nonfunctional allele (heterozygous) have intermediate activity. Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. TPMT testing may also be considered in patients with abnormal CBC results that do not respond to dose reduction. Early drug discontinuation in these patients is advisable.<span class="Bold"> TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE TABLETS.</span> See <a href="#i4i_clinical_pharmacology_id_df034bd4-87d9-40b3-99f9-5bfe3d8cf37d">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_warnings_id_da19e3c9-77ce-47f9-8707-52c7a4018fa1">WARNINGS</a>, <a href="#i4i_adverse_effects_id_eaa77ecc-3919-44c0-92c4-ee850ed35eac">ADVERSE REACTIONS</a> and <a href="#i4i_dosage_admin_id_001e484d-2965-4ed3-ba3a-f97ac5d4cc8b">DOSAGE AND ADMINISTRATION</a> sections.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_633d8de3-cf51-4abe-b607-73d61b8566e8"></a><a name="section-6.4"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d9a8c06a-ca91-4932-91ae-74d6b1774c10"></a><a name="section-6.4.1"></a><p></p>
<h3>Use with Allopurinol</h3>
<p class="First">One of the pathways for inactivation of azathioprine is inhibited by allopurinol. Patients receiving azathioprine tablets and allopurinol concomitantly should have a dose reduction of azathioprine tablets, to approximately 1/3 to 1/4 the usual dose. It is recommended that a further dose reduction or alternative therapies be considered for patients with low or absent TPMT activity receiving azathioprine tablets and allopurinol because both TPMT and XO inactivation pathways are affected. See <a href="#i4i_clinical_pharmacology_id_df034bd4-87d9-40b3-99f9-5bfe3d8cf37d">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_warnings_id_da19e3c9-77ce-47f9-8707-52c7a4018fa1">WARNINGS</a>, <a href="#i4i_lab_tests_id_6488bc0c-14b2-4c9f-855a-43a66e04b55d">PRECAUTIONS: Laboratory Tests</a> and <a href="#i4i_adverse_effects_id_eaa77ecc-3919-44c0-92c4-ee850ed35eac">ADVERSE REACTIONS</a>  sections.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_22a75f1b-af0c-4885-836d-924ace5472db"></a><a name="section-6.4.2"></a><p></p>
<h3>Use with Aminosalicylates</h3>
<p class="First">There is <span class="Italics">in vitro</span> evidence that aminosalicylate derivatives (e.g., sulphasalazine, mesalazine, or olsalazine) inhibit the TPMT enzyme. Concomitant use of these agents with azathioprine tablets should be done with caution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_de664f61-7096-4d77-9ded-223f00766fb5"></a><a name="section-6.4.3"></a><p></p>
<h3>Use with Other Agents Affecting Myelopoiesis</h3>
<p class="First">Drugs which may affect leukocyte production, including cotrimoxazole, may lead to exaggerated <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, especially in renal transplant recipients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a3b43a7e-284c-4d30-82ca-9ab501f64e99"></a><a name="section-6.4.4"></a><p></p>
<h3>Use with Angiotensin-Converting Enzyme Inhibitors</h3>
<p class="First">The use of angiotensin-converting enzyme inhibitors to control <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in patients on azathioprine has been reported to induce <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and severe <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7a155f5c-9279-4d93-a95d-e34c75abcd20"></a><a name="section-6.4.5"></a><p></p>
<h3>Use with Warfarin</h3>
<p class="First">Azathioprine tablets may inhibit the anticoagulant effect of warfarin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_d926aad5-a157-4a16-8651-42764d66173b"></a><a name="section-6.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">See <a href="#i4i_warnings_id_da19e3c9-77ce-47f9-8707-52c7a4018fa1">WARNINGS</a> section.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_c1f67c14-ed4f-4b86-a8e2-8ab6fe852422"></a><a name="section-6.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_d2978b93-3cc1-47cf-8ff5-f13523f47cb6"></a><a name="section-6.6.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f8d01957-a00f-4dd1-8114-832ec7197d50"></a><a name="section-6.6.1.1"></a><p></p>
<h4><span class="Bold">Pregnancy Category D</span></h4>
<p class="First">See <a href="#i4i_warnings_id_da19e3c9-77ce-47f9-8707-52c7a4018fa1">WARNINGS</a> section.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_296740e7-2a31-454f-9430-ff633322aed5"></a><a name="section-6.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">The use of azathioprine tablets in nursing mothers is not recommended. Azathioprine or its metabolites are transferred at low levels, both transplacentally and in breast milk. <span class="Sup">17, 18, 19</span> Because of the potential for tumorigenicity shown for azathioprine, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_1237b2d1-0acf-43a4-b567-8143192db439"></a><a name="section-6.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and efficacy of azathioprine in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_eaa77ecc-3919-44c0-92c4-ee850ed35eac"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The principal and potentially serious toxic effects of azathioprine tablets are hematologic and gastrointestinal. The risks of <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span> and neoplasia are also significant (see <a href="#i4i_warnings_id_da19e3c9-77ce-47f9-8707-52c7a4018fa1">WARNINGS</a>). The frequency and severity of adverse reactions depend on the dose and duration of azathioprine tablets as well as on the patient’s underlying disease or concomitant therapies. The incidence of hematologic toxicities and neoplasia encountered in groups of renal homograft recipients is significantly higher than that in studies employing azathioprine tablets for <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>. The relative incidences in clinical studies are summarized below:</p>
<table>
<col width="25%">
<col width="18%">
<col width="22%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Data on the rate and risk of neoplasia among persons with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> treated with azathioprine are limited. The incidence of lymphoproliferative disease in patients with RA appears to be significantly higher than that in the general population. In one completed study, the rate of lymphoproliferative disease in RA patients receiving higher than recommended doses of azathioprine (5 mg/kg/day) was 1.8 cases per 1,000 patient-years of follow-up, compared with 0.8 cases per 1,000 patient-years of follow-up in those not receiving azathioprine. However, the proportion of the increased risk attributable to the azathioprine dosage or to other therapies (i.e., alkylating agents) received by patients treated with azathioprine cannot be determined.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Toxicity</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">Renal Homograft</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> (any degree)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">&gt; 50%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">28%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">&lt; 2500 cells/mm3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">16%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5.3%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">20%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">&lt; 1%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Neoplasia</p></td>
<td class="Rrule" valign="top"></td>
<td class="Rrule" align="center" valign="top"><p class="First"><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">0.5%</p></td>
<td class="Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    Others</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2.8%</p></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e6a7d847-d3f0-4309-9c98-a007a8953b4c"></a><a name="section-7.1"></a><p></p>
<h2>Hematologic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> and/or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> are dose dependent and may occur late in the course of therapy with azathioprine tablets. Dose reduction or temporary withdrawal may result in reversal of these toxicities. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> may occur as a secondary manifestation of bone marrow suppression or <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, but the incidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in renal homotransplantation is 30 to 60 times that in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>. <span class="product-label-link" type="condition" conceptid="4308125" conceptname="Macrocytic anemia">Macrocytic anemia</span> and/or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> have been reported. </p>
<p> TPMT genotyping or phenotyping can help identify patients with low or absent TPMT activity (homozygous for nonfunctional alleles) who are at increased risk for severe, life threatening <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> from azathioprine tablets. See <a href="#i4i_clinical_pharmacology_id_df034bd4-87d9-40b3-99f9-5bfe3d8cf37d">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_warnings_id_da19e3c9-77ce-47f9-8707-52c7a4018fa1">WARNINGS</a> and <a href="#i4i_lab_tests_id_6488bc0c-14b2-4c9f-855a-43a66e04b55d">PRECAUTIONS: Laboratory Tests</a>. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> associated with <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> has been reported in patients with absent TPMT activity receiving azathioprine. <span class="Sup">6, 20</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f04b59db-e4c3-4a18-9dd6-a338f2650099"></a><a name="section-7.2"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may occur within the first few months of therapy with azathioprine tablets and occurred in approximately 12% of 676 <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients. The frequency of gastric disturbance often can be reduced by administration of the drug in divided doses and/or after meals. However, in some patients, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may be severe and may be accompanied by symptoms such as <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span> (see <a href="#i4i_precautions_id_bec768e0-4d9d-485d-8c61-c72d16dd0a6f">PRECAUTIONS</a>). <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> may occur rarely with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Hepatotoxicity manifest by elevation of serum alkaline phosphatase, bilirubin, and/or serum transaminases is known to occur following azathioprine use, primarily in allograft recipients. Hepatotoxicity has been uncommon (less than 1%) in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients. Hepatotoxicity following transplantation most often occurs within 6 months of transplantation and is generally reversible after interruption of azathioprine tablets. A rare, but life threatening hepatic veno-occlusive disease associated with chronic administration of azathioprine has been described in transplant patients and in one patient receiving azathioprine tablets for <span class="product-label-link" type="condition" conceptid="439014" conceptname="Panuveitis">panuveitis</span>.<span class="Sup">21, 22, 23</span> Periodic measurement of serum transaminases, alkaline phosphatase, and bilirubin is indicated for early detection of hepatotoxicity. If hepatic veno-occlusive disease is clinically suspected, azathioprine tablets should be permanently withdrawn.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a3d0b458-d279-40e0-bb7f-508124954fe3"></a><a name="section-7.3"></a><p></p>
<h2>Others</h2>
<p class="First">Additional side effects of low frequency have been reported. These include <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200146" conceptname="Pancreatic steatorrhea">steatorrhea</span>, negative nitrogen balance, and reversible <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span> and hepatosplenic T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_a5349abb-f776-4f73-82cc-6a1289fe8345"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The oral LD50s for single doses of azathioprine tablets in mice and rats are 2500 mg/kg and 400 mg/kg, respectively. Very large doses of this antimetabolite may lead to <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow hypoplasia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. About 30% of azathioprine tablets are bound to serum proteins, but approximately 45% is removed during an 8-hour hemodialysis.<span class="Sup">24</span> A single case has been reported of a renal transplant patient who ingested a single dose of 7500 mg azathioprine tablets. The immediate toxic reactions were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, followed by mild <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and mild abnormalities in liver function. The white blood cell count, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, and bilirubin returned to normal 6 days after the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_001e484d-2965-4ed3-ba3a-f97ac5d4cc8b"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE TABLETS.</span> TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity. Patients with low or absent TPMT activity are at an increased risk of developing severe, life threatening myelotoxicity from azathioprine tablets if conventional doses are given. Physicians may consider alternative therapies for patients who have low or absent TPMT activity (homozygous for nonfunctional alleles). Azathioprine tablets should be administered with caution to patients having one nonfunctional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in patients with reduced TPMT activity. Early drug discontinuation may be considered in patients with abnormal CBC results that do not respond to dose reduction.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a72565a1-bcde-47df-84a3-d8eaee24ae0f"></a><a name="section-9.1"></a><p></p>
<h2>Renal Homotransplantation</h2>
<p class="First">The dose of azathioprine tablets required to prevent rejection and minimize toxicity will vary with individual patients; this necessitates careful management. The initial dose is usually 3 to 5 mg/kg daily, beginning at the time of transplant. Azathioprine tablets are usually given as a single daily dose on the day of, and in a minority of cases 1 to 3 days before, transplantation. Azathioprine tablets are often initiated with the intravenous administration of the sodium salt, with subsequent use of tablets (at the same dose level) after the postoperative period. Intravenous administration of the sodium salt is indicated only in patients unable to tolerate oral medications. Dose reduction to maintenance levels of 1 to 3 mg/kg daily is usually possible. The dose of azathioprine tablets should not be increased to toxic levels because of threatened rejection. Discontinuation may be necessary for severe hematologic or other toxicity, even if rejection of the homograft may be a consequence of drug withdrawal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8112720b-4f4c-4007-9442-58389b455490"></a><a name="section-9.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></h2>
<p class="First">Azathioprine tablets are usually given on a daily basis. The initial dose should be approximately 1 mg/kg (50 mg to 100 mg) given as a single dose or on a twice daily schedule. The dose may be increased, beginning at 6 to 8 weeks and thereafter by steps at 4-week intervals, if there are no serious toxicities and if initial response is unsatisfactory. Dose increments should be 0.5 mg/kg daily, up to a maximum dose of 2.5 mg/kg per day. Therapeutic response occurs after several weeks of treatment, usually 6 to 8; an adequate trial should be a minimum of 12 weeks. Patients not improved after 12 weeks can be considered refractory. Azathioprine tablets may be continued long-term in patients with clinical response, but patients should be monitored carefully, and gradual dosage reduction should be attempted to reduce risk of toxicities.</p>
<p> Maintenance therapy should be at the lowest effective dose, and the dose given can be lowered decrementally with changes of 0.5 mg/kg or approximately 25 mg daily every 4 weeks while other therapy is kept constant. The optimum duration of maintenance azathioprine tablets has not been determined. Azathioprine tablets can be discontinued abruptly, but delayed effects are possible.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7e0aa28e-c131-4244-aeb8-a5b5b45ed126"></a><a name="section-9.3"></a><p></p>
<h2>Use in Renal Dysfunction</h2>
<p class="First">Relatively oliguric patients, especially those with <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">tubular necrosis</span> in the immediate postcadaveric transplant period, may have delayed clearance of azathioprine tablets or its metabolites, may be particularly sensitive to this drug, and are usually given lower doses.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_8317315a-27f6-4f5b-a322-c7ef76c79adf"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Azathioprine Tablets USP, 50 mg are round, yellow, flat faced tablets debossed with <span class="Bold">A</span> to the left of the score and <span class="Bold">Z</span> to the right of the score on one side of the tablet and blank on the other side. They are available as follows:</p>
<p>NDC 51079-620-06 - Unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages of 50 (5 cards of 10 tablets each). </p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] in a dry place and protect from light.</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_0c30b11f-7d78-403c-8802-b1bcba62e2e2"></a><a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329-339.</dd>
<dt>2.</dt>
<dd>Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos. 2001;29:601-605.</dd>
<dt>3.</dt>
<dd>McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus – implications for clinical pharmacogenomics. <span class="Italics">Pharmacogenomics</span>. 2002;3:89-98.</dd>
<dt>4.</dt>
<dd>Anstey A, Lennard L, Mayou SC, et al. <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Pancytopenia</span> related to azathioprine – an enzyme deficiency caused by a common genetic polymorphism: a review. <span class="Italics">JR Soc Med</span>. 1992; 85:752-756.</dd>
<dt>5.</dt>
<dd>Stolk JN, Beorbooms AM, de Abreu RA, et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>. <span class="Italics"><span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span> Rheum</span>. 1998; 41:1858-1866.</dd>
<dt>6.</dt>
<dd>Data on file, Prometheus Laboratories Inc.</dd>
<dt>7.</dt>
<dd>Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine<br>S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. <span class="Italics">Ann Intern Med. </span>1997; 126:608-614.</dd>
<dt>8.</dt>
<dd>Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. <span class="Italics">Ann Intern Med</span>. 1998; 129:716-718.</dd>
<dt>9.</dt>
<dd>Clunie GP, Lennard L. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology. 2004; 43:13-18.</dd>
<dt>10.</dt>
<dd>Clark JM. The mutagenicity of azathioprine in mice, Drosophila melanogaster, and Neurospora crassa. <span class="Italics">Mutat Res. </span>1975; 28:87-99.</dd>
<dt>11.</dt>
<dd>Data on file, Prometheus Laboratories Inc.</dd>
<dt>12.</dt>
<dd>Tagatz GE, Simmons RL. Pregnancy after renal transplantation. <span class="Italics">Ann Intern Med</span>. 1975; 82:113-114. Editorial Notes.</dd>
<dt>13.</dt>
<dd>Cote’ CJ, Meuwissen HJ, Pickering RJ. Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy<span class="Italics">. J Pediatr</span>. 1974; 85:324-328.</dd>
<dt>14.</dt>
<dd>DeWitte DB, Buick MK, Cyran SE, et al. Neonatal <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> and severe combined <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> associated with antenatal administration of azathioprine and prednisone. <span class="Italics">J Pediatr</span>. 1984; 105:625-628.</dd>
<dt>15.</dt>
<dd>Williamson RA, Karp LE. Azathioprine <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>: review of the literature and case report. <span class="Italics">Obstet Gynecol</span>. 1981; 58:247-250.</dd>
<dt>16.</dt>
<dd>Tallent MB, Simmons RL, Najarian JS. <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> in child of male recipient of kidney transplant. <span class="Italics">JAMA</span>. 1970; 211: 1854-1855.</dd>
<dt>17.</dt>
<dd>Data on file, Prometheus Laboratories Inc.</dd>
<dt>18.</dt>
<dd>Saarikoski S, Seppälä M. <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span> during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. <span class="Italics">Am J Obstet Gynecol</span>. 1973; 115:1100-1106.</dd>
<dt>19.</dt>
<dd>Coulam CB, Moyer TP, Jiang NS, et al. Breast-feeding after renal transplantation. <span class="Italics">Transplant Proc</span>. 1982; 14: 605-609.</dd>
<dt>20.</dt>
<dd>Schutz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> in thiopurine methyltransferase deficient heart transplant patients. Lancet. 1993; 341:436.</dd>
<dt>21.</dt>
<dd>Read AE, Wiesner RH, LaBrecque DR, et al. Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. <span class="Italics">Ann Intern Med</span>. 1986; 104:651-655.</dd>
<dt>22.</dt>
<dd>Katzka DA, Saul SH, Jorkasky D, et al. Azathioprine and hepatic veno-occlusive disease in renal transplant patients. <span class="Italics">Gastroenterology</span>. 1986; 90:446-454.</dd>
<dt>23.</dt>
<dd>Weitz H, Gokel JM, Loeshke K, et al. Veno-occlusive disease of the liver in patients receiving immunosuppressive therapy. <span class="Italics">Virchows Arch A Pathol Anat Histol</span>. 1982; 395:245-256.</dd>
<dt>24.</dt>
<dd>Schusziarra V, Ziekursch V, Schlamp R, et al. Pharmacokinetics of azathioprine under haemodialysis. <span class="Italics">Int J Clin Pharmacol Biopharm</span>. 1976; 14:298-302.</dd>
</dl>
<p class="First">Manufactured by:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p>Distributed by:<br><span class="Bold">Mylan Institutional Inc.</span><br>Rockford, IL 61103 U.S.A.</p>
<p>S-12074<br>1/14</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_34281bf0-6779-41b7-ab48-66ef8a2153f5"></a><a name="section-12"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 50 mg</span></p>
<p>NDC 51079-620-06</p>
<p><span class="Bold">Azathioprine</span><br><span class="Bold">Tablets, USP</span><br><span class="Bold">50 mg</span></p>
<p>50 Tablets (5 x 10)</p>
<p>Each tablet contains:<br>Azathioprine, USP . . . . 50 mg</p>
<p><span class="Bold">Usual Dosage: </span>See accompanying<br>prescribing information.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room Temperature.]</span><br><span class="Bold">Store in a dry place and</span><br><span class="Bold">protect from light.</span></p>
<p>Manufactured by:<span class="Bold"><br>Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Rx only</span></p>
<p>S-10812 R2</p>
<p>Packaged and Distributed by:</p>
<p><span class="Bold">Mylan Institutional Inc.</span></p>
<p>Rockford, IL 61103 U.S.A.</p>
<p>This unit dose package is not child resistant.</p>
<p>For institutional use only.</p>
<p>Keep this and all drugs out of the reach of children.</p>
<p>This container provides light-resistance.</p>
<p>See window for lot number and expiration date.</p>
<div class="Figure">
<a name="id1695428537"></a><img alt="Azathioprine 50 mg Tablet Unit Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e385894f-212b-4582-a63a-a0767fd97645&amp;name=4a0b69ca-0539-4e36-9cdc-3caa663795c5-03.jpg">
</div>
<div class="Figure">
<a name="id-42299613"></a><img alt="Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e385894f-212b-4582-a63a-a0767fd97645&amp;name=4a0b69ca-0539-4e36-9cdc-3caa663795c5-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AZATHIOPRINE 		
					</strong><br><span class="contentTableReg">azathioprine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51079-620</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AZATHIOPRINE</strong> (AZATHIOPRINE) </td>
<td class="formItem">AZATHIOPRINE</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">A;Z</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51079-620-06</td>
<td class="formItem">50  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51079-620-01</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075568</td>
<td class="formItem">07/23/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Institutional Inc.
							(039615992)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Mylan Institutional Inc. (039615992)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>4a0b69ca-0539-4e36-9cdc-3caa663795c5</div>
<div>Set id: e385894f-212b-4582-a63a-a0767fd97645</div>
<div>Version: 3</div>
<div>Effective Time: 20140103</div>
</div>
</div> <div class="DistributorName">Mylan Institutional Inc.</div></p>
</body></html>
